Skorvanek Matej, Martinez-Martin Pablo, Kovacs Norbert, Rodriguez-Violante Mayela, Corvol Jean-Christophe, Taba Pille, Seppi Klaus, Levin Oleg, Schrag Anette, Foltynie Thomas, Alvarez-Sanchez Mario, Arakaki Tomoko, Aschermann Zsuzsanna, Aviles-Olmos Iciar, Benchetrit Eve, Benoit Charline, Bergareche-Yarza Alberto, Cervantes-Arriaga Amin, Chade Anabel, Cormier Florence, Datieva Veronika, Gallagher David A, Garretto Nelida, Gdovinova Zuzana, Gershanik Oscar, Grofik Milan, Han Vladimir, Huang Jing, Kadastik-Eerme Liis, Kurtis Monica M, Mangone Graziella, Martinez-Castrillo Juan Carlos, Mendoza-Rodriguez Amelia, Minar Michal, Moore Henry P, Muldmaa Mari, Mueller Christoph, Pinter Bernadette, Poewe Werner, Rallmann Karin, Reiter Eva, Rodriguez-Blazquez Carmen, Singer Carlos, Tilley Barbara C, Valkovic Peter, Goetz Christopher G, Stebbins Glenn T
Department of Neurology P. J. Safarik University Kosice Slovak Republic.
Department of Neurology University Hospital L. Pasteur Kosice Slovak Republic.
Mov Disord Clin Pract. 2017 Mar 11;4(4):536-544. doi: 10.1002/mdc3.12476. eCollection 2017 Jul-Aug.
The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a newly developed tool to assess Parkinson's disease (PD). Changes in scores on the scale over the course of PD, including increasing disease duration and Hoehn and Yahr (HY) stages, have not been described. The objectives of this study were to analyze MDS-UPDRS scores on Parts I through IV and their differences based on HY stage and disease duration in a large cohort of patients with PD.
For this cross-sectional study, demographic data and MDS-UPDRS scores were collected, including HY stage. Subscores on MDS-UPDRS Parts I through IV were analyzed using 1-way analyses of variance for each HY stage and in 5-year increments of disease duration. Part III (motor assessment) scores were analyzed separately for on and off states.
The mean age of the 3206 patients was 65.8 ± 10.6 years, 53.3% were men, the mean disease duration was 11.5 ± 4.6 years, and the median HY stage was 2 (range, 0-5); 2156 patients were examined in an on state and 987 were examined in an off state. Scores for all MDS-UPDRS parts increased significantly through HY stages 1 through 5, with an average increase of 3.8, 7.7, 14.6, and 2.0 points consecutively for parts I through IV, respectively. For the 5-year increments of disease duration, MDS-UPDRS subscores increased by an average of 1.6, 3.3, 4.2, and 1.4 points consecutively for parts I through IV, respectively. This increase was significant only during the first 15 years of disease for all 4 parts, including part III scores evaluated in both on and off states.
MDS-UPDRS scores for all 4 parts increase significantly with every HY stage and also with 5-year increments of disease duration in the first 15 years of the disease.
运动障碍学会统一帕金森病评定量表（MDS - UPDRS）是一种新开发的用于评估帕金森病（PD）的工具。该量表评分在PD病程中的变化，包括疾病持续时间增加以及霍恩和雅尔（HY）分期变化，尚未得到描述。本研究的目的是分析一大群PD患者中MDS - UPDRS第一至四部分的评分及其基于HY分期和疾病持续时间的差异。
对于这项横断面研究，收集了人口统计学数据和MDS - UPDRS评分，包括HY分期。使用单因素方差分析对每个HY分期以及以5年为增量的疾病持续时间，分析MDS - UPDRS第一至四部分的子评分。第三部分（运动评估）评分分别针对开期和关期进行分析。
3206例患者的平均年龄为65.8±10.6岁，男性占53.3%，平均疾病持续时间为11.5±4.6年，HY分期中位数为2（范围0 - 5）；2156例患者在开期接受检查，987例患者在关期接受检查。所有MDS - UPDRS部分的评分在HY分期1至5期均显著增加，第一至四部分分别平均连续增加3.8、7.7、14.6和2.0分。对于以5年为增量的疾病持续时间，MDS - UPDRS子评分第一至四部分分别平均连续增加1.6、3.3、4.2和1.4分。这种增加仅在疾病的前15年对所有4个部分显著，包括在开期和关期评估的第三部分评分。
在疾病的前15年，MDS - UPDRS所有4个部分的评分随每个HY分期以及5年的疾病持续时间增加而显著增加。
